Utilizing State-of-the-Art DEL Technology to Discover Compounds That Hit Challenging Therapeutic Targets
DNA-encoded small molecule libraries (DELs) created using combinatorial chemistry and synthetic oligonucleotides are being successfully applied to drug discovery projects across the pharmaceutical industry. There have been many recent advances in DEL technology with the promise of helping to deliver ever more efficacious and beneficial small molecule-based tools and therapies. Here we review the state of the art of the use of DEL technology to uncover compounds that modulate challenging therapeutic targets, including the following applications: (1) identification of hits to targets in complex biological systems, (2) targeted protein degradation, (3) discovery of irreversible covalent binders, (4) identifying binders to nucleic acid targets and (5) enhanced hit identification using machine learning of DEL screen output. Register for this webinar to learn about leading advances in DEL technology.
Key takeaways
- Understand the state of the art and recent advances in DEL technologies
Presented By:
John (JP) Guilinger, Ph.D.
Director, Lead Discovery and Biochemistry